“SARMs” is a class of anabolic agents. Before you consider using a SARM, learn the facts here.

What are SARMs?

SARMs—short for “selective androgen receptor modulators”—are synthetic drugs designed to have effects similar to those of testosterone. SARMs are still in the research and testing stages for various medical conditions but have not been approved yet for any other use. Despite that, SARMs are readily available online and often marketed to bodybuilders as “legal steroids” or “steroid alternatives” or for “research only.”

Are SARMs safe or legal?

Although SARMs sometimes are sold in products marketed as dietary supplements, FDA has stated they are not dietary supplements and are unapproved by FDA for human use. The World Anti-Doping Agency (WADA) and National Collegiate Athletic Association (NCAA) prohibit SARMS for use in sport. All SARMs are also on the DoD Prohibited Dietary Supplement Ingredients list.

 

USU/CHAMP logo. Operation Supplement Safety logo. SARMs (Selective androgen receptor modulators) are unapproved drugs. They're also: illegally marketed and sold as dietary supplements, banned in all professional and college sports, unapproved by FDA for human use, known to adversely affect the liver and cholesterol levels. Is it worth the risk to your performance and readiness?

 

If you have purchased or considered using SARMs—including dietary supplement products labeled as containing a SARM (that is, with one or more SARMs on the Supplement Facts panel) and products marketed for research purposes only (and not for human consumption)—think again! SARMs pose significant health and readiness risks. They also might cause positive results if you are tested for steroids. Importantly, use of SARMs might interfere with the natural release of your own testosterone.

What ingredients should you look out for?

Some of the ingredient names to watch out for on dietary supplement product labels and websites include (but are not limited to) the following:

  • AC-262536 (Accadrine)
  • ACP-105 (Acadibol)
  • Andarine (S4, GTx 007)
  • Enobosarm (Ostarine, MK-2866, OTR-AC, S-22)
  • LGD-3303
  • LGD-4033 (Anabolicum, Ligandrol)
  • RAD-140 (Testolone, Vosilasarm)
  • RAD-150 (TLB-150, Sustalone)
  • S-23
  • YK-11

Watch out too for other experimental, unapproved drugs—such as GW-501516 (Cardarine), MK-677 (Ibutamoren), SR-9009 (Stenabolic), and SR-9011—that sometimes are marketed as SARMs. They aren’t, but they also are illegal for any use other than research. All unapproved drugs are prohibited for use by Service Members.

For a more complete list of names, please see “SARMs in dietary supplements.”

Updated 22 July 2022

References

Adami, P. E., Koutlianos, N., Baggish, A., Bermon, S., Cavarretta, E., Deligiannis, A., . . . Papadakis, M. (2022). Cardiovascular effects of doping substances, commonly prescribed medications and ergogenic aids in relation to sports: A position statement of the sport cardiology and exercise nucleus of the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 29(3), 559–575. doi:10.1093/eurjpc/zwab198

Aikawa, K., Miyawaki, T., Hitaka, T., Imai, Y. N., Hara, T., Miyazaki, J., . . . Yamamoto, S. (2015). Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part I. Bioorganic & Medicinal Chemistry, 23(10), 2568–2578. doi:10.1016/j.bmc.2015.03.032

Akhtar, N., Locke, D., & Stine, J. (2021). Harm by SARM: A case of drug-induced liver injury in an amateur bodybuilder. American Journal of Gastroenterology, 116(1), S1184–S1184. doi:10.14309/01.ajg.0000784936.08024.c4

Asano, M., Hitaka, T., Imada, T., Yamada, M., Morimoto, M., Shinohara, H., . . . Hasuoka, A. (2017). Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives. Bioorganic & Medicinal Chemistry Letters, 27(9), 1897–1901. doi:10.1016/j.bmcl.2017.03.038

Barbara, M., Dhingra, S., & Mindikoglu, A. L. (2020). Ligandrol (LGD-4033)-induced liver injury. ACG Case Reports Journal, 7(6). doi:10.14309/crj.0000000000000370

Bedi, H., Hammond, C., Sanders, D., Yang, H.-M., & Yoshida, E. M. (2021). Drug-induced liver injury from Enobosarm (Ostarine), a selective androgen receptor modulator. ACG Case Reports Journal, 8(1). doi:10.14309/crj.0000000000000518

Bertol, E., & Trignano, C. (2022). Poisoning caused by medicines and drugs of abuse. Toxics, 10(9). doi:10.3390/toxics10090515

Cardaci, T. D., Machek, S. B., Wilburn, D. T., Heileson, J. L., Harris, D. R., Cintineo, H. P., & Willoughby, D. S. (2022). LGD‐4033 and MK‐677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental Physiology, 107(12), 1467–1476. doi:10.1113/ep090741

Catalani, V., Negri, A., Townshend, H., Simonato, P., Prilutskaya, M., Tippett, A., & Corazza, O. (2021). The market of sport supplement in the digital era: A netnographic analysis of perceived risks, side-effects and other safety issues. Emerging Trends in Drugs, Addictions, and Health, 1. doi:10.1016/j.etdah.2021.100014

Chakrabarty, R., Grainger, J., Goebel, C., Brooker, L., & George, A. (2021). “For research use only”: A comprehensive analysis of SARMs and related IPEDs purchased on local Australian websites between 2017 and 2018. Performance Enhancement & Health, 9(3-4). doi:10.1016/j.peh.2021.100201

Coletti, D., & Adamo, S. (2015). Will exercise mimetics hold promise? Journal of Pharmacovigilance, 3(2), article 1000e1138. doi:10.4172/2329-6887.1000e138

Dalton, J. T. (2017). The long and winding road for selective androgen receptor modulators. British Journal of Clinical Pharmacology, 83(10), 2131–2133. doi:10.1111/bcp.13345

Efimenko, I. V., Valancy, D., Dubin, J. M., & Ramasamy, R. (2021). Adverse effects and potential benefits among selective androgen receptor modulators users: A cross-sectional survey. International Journal of Impotence Research, 34(8), 757–761. doi:10.1038/s41443-021-00465-0

Fragkaki, A. G., Sakellariou, P., Kiousi, P., Kioukia‐Fougia, N., Tsivou, M., Petrou, M., & Angelis, Y. (2018). Human in vivo metabolism study of LGD‐4033. Drug Testing and Analysis, 10(11-12), 1635–1645. doi:10.1002/dta.2512

Goldman, A. L., Pope, H. G., & Bhasin, S. (2019). The health threat posed by the hidden epidemic of anabolic steroid use and body image disorders among young men. The Journal of Clinical Endocrinology & Metabolism, 104(4), 1069–1074. doi:10.1210/jc.2018-01706

Gould, H. P., Hawken, J. B., Duvall, G. T., & Hammond, J. W. (2021). Asynchronous bilateral achilles tendon rupture with selective androgen receptor modulators. JBJS Case Connector, 11(2), article 635. doi:10.2106/jbjs.Cc.20.00635

Health Canada. (2013). GW501516 - Serious Risks Associated With the Use of the Unauthorized Product - For the Public.   Retrieved 17 January 2023 from https://recalls-rappels.canada.ca/en/alert-recall/gw501516-serious-risks-associated-use-unauthorized-product-public

Hilkens, L., Cruyff, M., Woertman, L., Benjamins, J., & Evers, C. (2021). Social media, body image and resistance training: Creating the perfect ‘me’ with dietary supplements, anabolic steroids and SARM’s. Sports Medicine - Open, 7(1), article 81. doi:10.1186/s40798-021-00371-1

Kanagalingam, G., Sostre Santiago, V., Kane, B., Shaw, J. C., Friedman, H., & Murthy, U. K. (2021). Selective androgen receptor modulator intake associated with liver injury in a patient with underlying heterozygous H63D and PIMZ mutation. American Journal of Therapeutics, 0(8 April 2021). doi:10.1097/mjt.0000000000001370

Khan, S., Fackler, J., Gilani, A., Murphy, S., & Polintan, L. (2022). Selective androgen receptor modulator induced hepatotoxicity. Cureus(15 February 2022), article 22239. doi:10.7759/cureus.22239

Kim, N. S., Choi, H. S., Lim, N. Y., Lee, J. H., Kim, H., & Baek, S. Y. (2022). Application of simultaneous analytical methods for selective androgen receptor modulator adulterated in dietary supplements advertised as muscle strengthening using UHPLC-PDA and LC–ESI–MS/MS. Chromatographia, 85(10-11), 895–919. doi:10.1007/s10337-022-04170-y

Kintz, P. (2021). The forensic response after an adverse analytical finding (doping) involving a selective androgen receptor modulator (SARM) in human athlete. Journal of Pharmaceutical and Biomedical Analysis, 207. doi:10.1016/j.jpba.2021.114433

Kintz, P., Gheddar, L., Paradis, C., Chinellato, M., Ameline, A., Raul, J.-S., & Oliva-Labadie, M. (2021). Peroxisome proliferator-activated receptor delta agonist (PPAR- δ) and selective androgen receptor modulator (SARM) abuse: Clinical, analytical and biological data in a case involving a poisonous combination of GW1516 (Cardarine) and MK2866 (Ostarine). Toxics, 9(10). doi:10.3390/toxics9100251

Koller, T., Vrbova, P., Meciarova, I., Molcan, P., Smitka, M., Adamcova Selcanova, S., & Skladany, L. (2021). Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review. World Journal of Clinical Cases, 9(16), 4062–4071. doi:10.12998/wjcc.v9.i16.4062

Lam, H., & Wong, S.-Y. (2021). At what cost: Drug-induced liver injury secondary to selective androgen receptor modulator. American Journal of Gastroenterology, 116(1), S1142–S1142. doi:10.14309/01.ajg.0000784452.64316.30

Leaney, A. E., Beck, P., Biddle, S., Brown, P., Grace, P. B., Hudson, S. C., & Mawson, D. H. (2020). Analysis of supplements available to UK consumers purporting to contain selective androgen receptor modulators. Drug Testing and Analysis, 13(1), 122–127. doi:10.1002/dta.2908

Leung, K., Yaramada, P., Goyal, P., Cai, C. X., Thung, I., & Hammami, M. B. (2022). RAD-140 drug-induced liver injury. Ochsner Journal, 22(4), 361–365. doi:10.31486/toj.22.0005

Li, S., & Laher, I. (2015). Exercise pills: At the starting line. Trends in Pharmacological Sciences, 36(12), 906–917. doi:10.1016/j.tips.2015.08.014

Machek, S. B., Cardaci, T. D., Wilburn, D. T., & Willoughby, D. S. (2020). Considerations, possible contraindications, and potential mechanisms for deleterious effect in recreational and athletic use of selective androgen receptor modulators (SARMs) in lieu of anabolic androgenic steroids: A narrative review. Steroids, 164. doi:10.1016/j.steroids.2020.108753

Miklos, A. (2018). Selective androgen receptor modulators (SARMs) in the context of doping. Farmacia, 66(5), 758–762. doi:10.31925/farmacia.2018.5.3

Mohideen, H., Hussain, H., Dahiya, D. S., & Wehbe, H. (2023). Selective androgen receptor modulators: An emerging liver toxin. Journal of Clinical and Translational Hepatology, 11(1), 188–196. doi:10.14218/jcth.2022.00207

Narayanan, R., Coss, C. C., & Dalton, J. T. (2018). Development of selective androgen receptor modulators (SARMs). Molecular and Cellular Endocrinology, 465, 134–142. doi:10.1016/j.mce.2017.06.013

Padappayil, R. P., Chandini Arjun, A., Vivar Acosta, J., Ghali, W., & Mughal, M. S. (2022). Acute myocarditis from the use of selective androgen receptor modulator (SARM) RAD-140 (Testolone). Cureus(7 January 2022), article 21663. doi:10.7759/cureus.21663

Palibroda, N., Zlotar, O., Fedyaeva, S., & Avramenko, A. (2018). Dietary supplements for bodybuilding: Is it safe for the liver? INTERNATIONAL ACADEMY JOURNAL Web of Scholar, 5(6 (24)), 6–10. doi:10.31435/rsglobal_wos/12062018/5775

Solomon, Z. J., Mirabal, J. R., Mazur, D. J., Kohn, T. P., Lipshultz, L. I., & Pastuszak, A. W. (2019). Selective androgen receptor modulators: Current knowledge and clinical applications. Sexual Medicine Reviews, 7(1), 84–94. doi:10.1016/j.sxmr.2018.09.006

Thevis, M., & Schänzer, W. (2018). Detection of SARMs in doping control analysis. Molecular and Cellular Endocrinology, 464, 34–45. doi:10.1016/j.mce.2017.01.040

Van Wagoner, R. M., Eichner, A., Bhasin, S., Deuster, P. A., & Eichner, D. (2017). Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. Jama, 318(20), article 2004. doi:10.1001/jama.2017.17069

Vasilev, V., & Boyadjiev, N. (2020). Selective androgen receptor modulators (SARM) – a new temptation in sports. types, mode of action and side effects of their application: Review. Journal of Applied Sports Sciences, 2(2020), 107–115. doi:10.37393/jass.2020.02.9

Weinblatt, D., & Roy, S. (2022). Drug-induced liver injury secondary to enobosarm: A selective androgen receptor modulator. Journal of Medical Cases, 13(5), 244–248. doi:10.14740/jmc3937